Nurix Therapeutics, Inc. (NASDAQ:NRIX) Expected to Post Quarterly Sales of $9.59 Million

Equities analysts expect that Nurix Therapeutics, Inc. (NASDAQ:NRIXGet Rating) will announce $9.59 million in sales for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for Nurix Therapeutics’ earnings, with the highest sales estimate coming in at $11.54 million and the lowest estimate coming in at $8.00 million. Nurix Therapeutics posted sales of $7.09 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 35.3%. The firm is scheduled to issue its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that Nurix Therapeutics will report full-year sales of $49.54 million for the current fiscal year, with estimates ranging from $32.00 million to $70.05 million. For the next fiscal year, analysts anticipate that the business will report sales of $71.04 million, with estimates ranging from $35.30 million to $105.95 million. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that cover Nurix Therapeutics.

Nurix Therapeutics (NASDAQ:NRIXGet Rating) last released its quarterly earnings data on Thursday, April 7th. The company reported ($0.95) EPS for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.07). Nurix Therapeutics had a negative return on equity of 36.42% and a negative net margin of 394.21%.

NRIX has been the subject of several recent research reports. Needham & Company LLC reiterated a “buy” rating and issued a $48.00 price target on shares of Nurix Therapeutics in a report on Wednesday, January 5th. Robert W. Baird lowered their price target on Nurix Therapeutics from $49.00 to $41.00 in a report on Friday, January 28th. Zacks Investment Research upgraded Nurix Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. HC Wainwright initiated coverage on Nurix Therapeutics in a report on Wednesday, December 29th. They issued a “buy” rating and a $62.00 price target for the company. Finally, Wells Fargo & Company lowered their price target on Nurix Therapeutics from $28.00 to $25.00 and set an “equal weight” rating for the company in a report on Monday. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $47.00.

A number of large investors have recently bought and sold shares of NRIX. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Nurix Therapeutics during the fourth quarter worth about $117,000. Ensign Peak Advisors Inc lifted its position in shares of Nurix Therapeutics by 512.0% during the fourth quarter. Ensign Peak Advisors Inc now owns 4,890 shares of the company’s stock worth $142,000 after purchasing an additional 4,091 shares during the last quarter. Allspring Global Investments Holdings LLC bought a new position in shares of Nurix Therapeutics during the fourth quarter worth about $178,000. Grace Capital lifted its position in shares of Nurix Therapeutics by 47.2% during the third quarter. Grace Capital now owns 6,727 shares of the company’s stock worth $190,000 after purchasing an additional 2,158 shares during the last quarter. Finally, Fiduciary Trust Co. bought a new position in shares of Nurix Therapeutics during the third quarter worth about $200,000. 87.30% of the stock is owned by institutional investors.

NRIX stock opened at $12.37 on Tuesday. Nurix Therapeutics has a 52 week low of $12.34 and a 52 week high of $37.42. The firm has a market cap of $554.84 million, a P/E ratio of -4.06 and a beta of 2.74. The business’s fifty day moving average price is $15.24.

About Nurix Therapeutics (Get Rating)

Nurix Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.

Further Reading

Get a free copy of the Zacks research report on Nurix Therapeutics (NRIX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Nurix Therapeutics (NASDAQ:NRIX)

Receive News & Ratings for Nurix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nurix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.